The High Court has cleared the way for the first judicial review challenging how the National Institute for Health and Clinical Excellence reaches decisions on drug recommendations.
Alzheimer's drug manufacturer Eisai and its co-promotion partner Pfizer were granted permission for a review yesterday on the decision by NICE not to recommend Aricept for NHS patients with newly-diagnosed, mild Alzheimer's disease.
The High Court has cleared the way for the first judicial review challenging how the National Institute for Health and Clinical Excellence reaches decisions on drug recommendations.
Alzheimer's drug manufacturer Eisai and its co-promotion partner Pfizer were granted permission for a review yesterday on the decision by NICE not to recommend Aricept for NHS patients with newly-diagnosed, mild Alzheimer's disease.
No comments yet